Patent FR1252209A successfully refreshed from Google Patents.
Patent EP0578932A2 successfully refreshed from Google Patents.
EP0578932A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
IL-2 receptor gamma chain molecule
Assignee: Ajinomoto Co Inc
•
Filing: 1993-04-22
•
Granted: —
•
Expires: 2013-04-22
Abstract
Abstract The present invention relates to an IL-2 receptor γ chain molecule, a DNA-sequence encoding the IL-2 receptor γ chain molecule, a vector possessing said DNA-sequence, a cell transformed with said vector, a method for the production of an IL-2 receptor γ chain molecule by culturing of said cell, an immune response regulatory agent comprising an Il-2 receptor γ chain molecule and an antibody to an IL-2 receptor γ chain molecule. Both the Il-2 receptor γ chain molecule and the antibody to the IL-2 receptor γ chain molecule are very useful immune response regulatory agents.
Inventors
- 👤 Kazuo Sugamura
- 👤 Toshikazu Takeshita
- 👤 Hironobu Asao
- 👤 Masataka Nakamura
- 👤 Toshiro C/O Central Research Lab. Shimamura
- 👤 Manabu c/o Central Research Lab. Suzuki
- 👤 Junji C/O Central Research Lab. Hamuro
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 14:20
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/715; C07K14/7155; A; A61; A61P; A61P37/00; A61K; A61K38/00
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
17 words
An Interleukin-2 receptor γ-chain polypeptide, which is substantially free of the other components of the Interleukin-2 receptor.
Claim 2
Dependent Claim
16 words
A human Interleukin-2 receptor γ-chain polypeptide, which is substantially free of the α- and the β-chain.
Claim 3
Dependent Claim
92 words
An Interleukin-2 receptor γ-chain polypeptide according to claim 1 or claim 2, which is selected from the following group: (a) a polypeptide having the following amino acid sequence: (Seq ID. No.4) (b) a polypeptide, which is deficient in one or more amino acids; (c) a polypeptide, in which in respect to (a) and/or (b) one or more amino acids are replaced; (d) a fusion polypeptide comprising a polypeptide according to (a), (b) or (c). (e) a polypeptide, which is an allelic derivative of a polypeptide according to (a), (b), (c) or (d).
Claim 4
Dependent Claim
93 words
An Interleukin-2 receptor γ-chain polypeptide according to claim 1 or claim 2, which is selected from the following group: (a) a polypeptide having the following amino acid sequence: (Seq. Id. No. 5) (b) a polypeptide, which is deficient in one or more amino acids; (c) a polypeptide, in which in respect to (a) and/or (b) one or more amino acids are replaced; (d) a fusion polypeptide comprising a polypeptide according to (a), (b) or (c); (e) a polypeptide, which is an allelic derivative of a polypeptide according to (a), (b), (c) or (d).
Claim 5
Dependent Claim
125 words
An Interleukin-2 receptor γ-chain polypeptide according to claim 1 or claim 2, which is selected from the following group: (a) a polypeptide having the following amino acid sequence: (Seq. Id. No. 6) (b) a polypeptide, which is deficient in one or more amino acids; (c) a polypeptide, in which in respect to (a) and/or (b) one or more amino acids are replaced; (d) a fusion polypeptide comprising a polypeptide according to (a), (b) or (c). (e) a polypeptide, which is an allelic derivative of a polypeptide according to (a), (b), (c) or (d); (f) a polypeptide, which lacks the signal peptide with respect to (a), (b), (c) or (e); (g) a polypeptide, comprises the sequence in (a) of from - 22 (Met) to -1 (Gly).
Claim 6
Dependent Claim
16 words
An Interleukin-2 receptor γ-chain polypeptide according to any of the preceding claims, which is water soluble.
Claim 7
Dependent Claim
16 words
An Interleukin-2 receptor γ-chain polypeptide according to any of the preceding claims, which is chemically modified.
Claim 8
Dependent Claim
25 words
An Interleukin-2 receptor γ-chain polypeptide according to any of the preceding claims, which is modified by way of acetylation and/or amidation and/or treatment with polyethylene.
Claim 9
Dependent Claim
16 words
A DNA sequence coding for a polypeptide according to any of the claims 1 to 6.
Claim 10
Dependent Claim
19 words
A DNA sequence according to claim 9, which is represented by the following nucleotide sequence: (Seq. Id. No. 7)
Claim 11
Dependent Claim
19 words
A DNA sequence according to claim 9, which is represented by the following nucleotide sequence: (Seq. Id. No. 6)
Claim 12
Dependent Claim
19 words
A DNA sequence according to claim 9, which is represented by the following nucleotide sequence: (Seq. Id. No. 5)
Claim 13
Dependent Claim
19 words
A DNA sequence according to claim 9, which is represented by the following nucleotide sequence: (Seq. Id. No. 4)
Claim 14
Dependent Claim
36 words
A DNA sequence according to any of the claims 9 to 13, which has an altered nucleotide sequence due to the degeneracy of the genetic code, point mutations, induced mutations or represents an allelic variant thereof.
Claim 15
Dependent Claim
14 words
A vector including a DNA-sequence according to any of the claims 9 to 14.
Claim 16
Dependent Claim
11 words
A vector according to claim 15, which is an expression vector.
Claim 17
Dependent Claim
16 words
A vector according to claims 15 or 16, which can be propagated in an eucaryotic cell.
Claim 18
Dependent Claim
16 words
A vector according to claims 15 or 16, which can be propagated in an procaryotic cell.
Claim 19
Dependent Claim
15 words
A cell transformed with a DNA-sequence according to any of the claims 9 to 14.
Claim 20
Dependent Claim
15 words
A cell transformed with a vector according to any of the claims 15 to 17.
Claim 21
Dependent Claim
13 words
A cell according to claim 19 or 20, which is an eucaryotic cell.
Claim 22
Dependent Claim
13 words
A cell according to claim 19 or 20, which is an procaryotic cell.
Claim 23
Dependent Claim
11 words
A cell according to claim 21, which is a CHO cell.
Claim 24
Dependent Claim
12 words
A cell according to claim 21, which is a mouse L929 cell.
Claim 25
Dependent Claim
13 words
A cell according to claim 22, which is of the genus E. coli.
Claim 26
Dependent Claim
10 words
A cell according to claim 20, which is [FERM BP-4199].
Claim 27
Dependent Claim
10 words
A cell according to claim 20, which is [FERM BP-4200].
Claim 28
Independent Claim
31 words
A method for the production of an Interleukin-2 receptor γ-chain polypeptide, comprising, culturing a cell according to any of the claims 18 to 26, and isolating said Interleukin-2 receptor γ-chain polypeptide.
Claim 29
Dependent Claim
28 words
A method for the production of an Interleukin-2 receptor γ-chain polypeptide according to claim 28, wherein the Interleukin-2 receptor γ-chain polypeptide is the human Interleukin-2 receptor γ-chain polypeptide.
Claim 30
Dependent Claim
17 words
An antibody, capable of binding to a polypeptide according to any of the claims 1 to 8.
Claim 31
Dependent Claim
11 words
An antibody according to claim 30, which is a monoclonal antibody.
Claim 32
Dependent Claim
15 words
A pharmaceutical composition, including a polypeptide according to any of the claims 1 to 8.
Claim 33
Dependent Claim
15 words
A pharmaceutical composition, including an antibody according to any of the claims 29 to 30.
Claim 34
Dependent Claim
18 words
A pharmaceutical composition according to any of the claims 32 to 33, which comprises a pharmaceutical acceptable carrier.
Claim 35
Dependent Claim
19 words
Use of a pharmaceutical composition according to any of the claims 32 to 34 as an immune regulatory agent.
Claim 36
Independent Claim
31 words
A method for the assay or detection of a gene encoding IL-2 receptor γ-chain polypeptide in a sample using a DNA sequence according to any of the claims 9 to 14.
Claim 37
Independent Claim
30 words
A method for the assay or detection of a gene encoding IL-2 receptor γ-chain polypeptide in a sample using an antibody according to any of the claims 30 to 31.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.